Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Binder

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Medical Economics|May 17, 2019
Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomitingSang Hee Park, Gary Binder, Shelby Corman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2019
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysisMarc Botteman, Katharina Nickel, Shelby Corman, et al.
Journal of Medical Economics|December 15, 2015
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myelomaClaire Lee, Matthew Grigorian, Ryan Nolan, et al.
Frontiers in Medicine|July 19, 2021
A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort StudyChristiane Querfeld, Theresa Pacheco, Bradley Haverkos, et al.
Journal of Medical Economics|January 4, 2013
Total cost comparison in relapsed/refractory multiple myelomaBrian Durie, Gary Binder, Chris Pashos, et al.
Leukemia Research|October 28, 2017
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Quanhong Ni, et al.
Future Oncology (London, England)|April 21, 2021
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysisRudolph M Navari, Gary Binder, Erminio Bonizzoni, et al.
Leukemia Research|August 19, 2017
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independenceChristopher R Cogle, Sheila R Reddy, Eunice Chang, et al.
Leukemia & Lymphoma|May 10, 2017
Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Syed Rizvi, et al.
Blood Neoplasia|October 2, 2025
Ivosidenib or venetoclax combined with hypomethylating agents in <i>IDH1</i>-mutated acute myeloid leukemia: a real-world studyCurtis A Lachowiez, B Douglas Smith, Alexander Joseph Ambinder, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Medical Economics|May 17, 2019
Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomitingSang Hee Park, Gary Binder, Shelby Corman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2019
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysisMarc Botteman, Katharina Nickel, Shelby Corman, et al.
Journal of Medical Economics|December 15, 2015
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myelomaClaire Lee, Matthew Grigorian, Ryan Nolan, et al.
Frontiers in Medicine|July 19, 2021
A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort StudyChristiane Querfeld, Theresa Pacheco, Bradley Haverkos, et al.
Journal of Medical Economics|January 4, 2013
Total cost comparison in relapsed/refractory multiple myelomaBrian Durie, Gary Binder, Chris Pashos, et al.
Leukemia Research|October 28, 2017
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Quanhong Ni, et al.
Future Oncology (London, England)|April 21, 2021
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysisRudolph M Navari, Gary Binder, Erminio Bonizzoni, et al.
Leukemia Research|August 19, 2017
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independenceChristopher R Cogle, Sheila R Reddy, Eunice Chang, et al.
Leukemia & Lymphoma|May 10, 2017
Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Syed Rizvi, et al.
Blood Neoplasia|October 2, 2025
Ivosidenib or venetoclax combined with hypomethylating agents in <i>IDH1</i>-mutated acute myeloid leukemia: a real-world studyCurtis A Lachowiez, B Douglas Smith, Alexander Joseph Ambinder, et al.
Pageof 2